久久精品在线视频-久久精品在这里-久久精品这里-久久精品这里精品-久久精品这里热有精品-久久精品这里热有精品2015

BioChain Engineering Research System  

for Key Technologies in the Prevention and Control of Chronic Diseases

Engineering R&D drives high-tech innovations, constructing a comprehensive solution for the “Triple E*” approach to chronic diseases.

Based on innovative liquid biopsy technology, BioChain has established a strategic research framework with the aim of developing proprietary methodologies for the early detection, diagnosis, and intervention (hereinafter referred to as “Triple E*”) of  chronic diseases such as cancer, cardiovascular disease, and cerebrovascular disease. Our research center comprises seven medical engineering research laboratories, including Epigenetics, Multi-omics Integration, Transcription, Proteomics, Bioinformatics, Automation, and Material Engineering laboratories. These laboratories provide guidance and assistance in applying and transforming clinical outcomes.

Proprietary Technologies

Sample Processing Technology

BioChain has developed the industry's first automated equipment for nucleic acid extraction and purification. It includes cell lysis, nucleic acid extraction and purification, and bisulfite conversion on a single automated platform. It can significantly reduces the testing time by 60% when compared to manual operation.

Liquid Biopsy Technology

BioChain offers a wide range of proprietary cfDNA extraction and laboratory preparation kits. Our cfDNA extraction kit can be used with various sample types, such as blood, plasma, and urine. It also delivers 20% higher extraction purity and efficiency compared to high-quality products in the market. Our laboratory preparation kit also uses a single-stranded cfDNA laboratory preparation method for methylation sequencing. Its optimal sequencing depth is 77% higher than other industry-leading products when the same amount of cfDNA is used.

Biomarker Discovery Technology

BioChain primarily integrates Whole Genome Bisulfite Sequencing (WGMS) and Next Generation Sequencing (NGS) methylation-specific panels to ensure sufficient sequencing coverage of cancer-related genes and to distinguish genome-wide methylation levels. A high-efficiency biomarker discovery procedure is achieved when it is combined with self-developed AI interpretation and standardized validation systems.

Pan-Cancer Early Detection

Our current service for the six high-risk cancers in China (lung, colorectal, gastric, esophageal, liver, and thyroid cancers) requires only 10 mL of peripheral blood and has an overall sensitivity, specificity, and tumor tissue-of-origin agreement rate of up to 91.0%, 95.3%, and 85.9%, respectively.(Data as of July 2023)

Artificial Intelligence (AI) Interpretation Technology

BioChain has built a high-performance computing (HPC) cluster with a computing capacity of over 200 trillion operations per second. Combined with its algorithm system, it can seamlessly execute quality control, sequence alignment, feature extraction, and other processes of high-throughput sequencing data, and build multi-dimensional comprehensive models. At present, BioChain has obtained more than ten exclusive algorithm patents related with the Multidimensional and Omics Data Integration Algorithm (MODE).

Industrialization Platform

BioChain has established an advanced industrialization platform and adheres strictly to the ISO13485 Quality Management System. With this approach, the company effectively executes all process stages, including project approval, product development, performance validation, production transfer, preclinical research, registration testing, clinical trials, registration declaration, and marketing authorization. In addition, BioChain operates an industrialization base covering almost 40,000 square meters in the Beijing Economic-Technological Development Area (BDA), enabling it to provide testing products and services to millions of individuals annually.

BioChain Pipeline

As a leader in the “Triple E*” approach to tackling chronic diseases,  BioChain started with a strong focus on gastrointestinal (GI) cancers and has now gradually expanded into dozens of other cancers, as well as other major diseases such as cardiovascular and cerebrovascular diseases.

主站蜘蛛池模板: 99九九精品免费视频观看 | 中文字幕1区2区 | 青青久草在线视频 | 手机看片久久高清国产日韩 | 国产精品66在线观看 | 国产一级特黄生活片 | 亚洲综合在线另类色区奇米 | 毛片网子| 伊人久久波多野结衣中文字幕 | 国产成人综合网 | 99久久伊人| 欧美 日韩 高清 | 久久国产精品高清一区二区三区 | 奇米影视7777久久精品 | 免费观看大片毛片 | 亚洲精品一区国产二区 | 精品国产日韩亚洲一区在线 | 欧美一级特黄毛片免费 | 九九精品在线播放 | 毛片视| 午夜性a一级毛片 | 性a爱片免费视频性 | 一级二级毛片 | 亚洲成色999久久网站 | 国产欧美日韩综合精品一区二区 | 天天射天天干天天插 | 韩国日本三级在线观看 | 日韩中文字幕网站 | 四虎在线最新地址公告 | 中国精品久久 | 多色视频 | 国产精品9999久久久久仙踪林 | 四虎在线精品观看免费 | 欧美一级爱操视频 | 亚洲综合激情五月色播 | 亚洲a视频在线 | 久草网在线| 视频一区二区在线 | 亚洲精品综合久久 | 在线黄色免费 | 久久香蕉国产线看观看乱码 |